{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:20:05Z","timestamp":1790400005421,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00259-019-04397-2","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T05:02:32Z","timestamp":1561957352000},"page":"2178-2189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":211,"title":["Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer\u2019s disease and other tauopathies"],"prefix":"10.1007","volume":"46","author":[{"given":"Heiko","family":"Kroth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Oden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Molette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno","family":"Schieferstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Capotosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Berndt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heribert","family":"Schmitt-Willich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Darmency","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Gabellieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Boudou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Juergens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvan","family":"Varisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthymia","family":"Vokali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Tamagnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Dinkelborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Muhs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5052-6586","authenticated-orcid":false,"given":"Andrew","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,1]]},"reference":[{"issue":"3","key":"4397_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jalz.2015.02.003","volume":"11","author":"A Alzheimer's","year":"2015","unstructured":"Alzheimer's A. Alzheimer's disease facts and figures. Alzheimers Dement. 2015;11(3):332\u201384.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"4397_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrd2896","volume":"9","author":"M Citron","year":"2010","unstructured":"Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov. 2010;9(5):387\u201398.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"4397_CR3","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1021\/jm5017544","volume":"58","author":"M Ariza","year":"2015","unstructured":"Ariza M, et al. Tau positron emission tomography (PET) imaging: past, present, and future. J Med Chem. 2015;58(11):4365\u201382.","journal-title":"J Med Chem"},{"issue":"2","key":"4397_CR4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00259-015-3208-1","volume":"43","author":"K Heurling","year":"2016","unstructured":"Heurling K, et al. Imaging beta-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis. Eur J Nucl Med Mol Imaging. 2016;43(2):362\u201373.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"4397_CR5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3233\/JAD-160821","volume":"56","author":"MN Sabbagh","year":"2017","unstructured":"Sabbagh MN, et al. Histopathology and Florbetaben PET in patients incorrectly diagnosed with Alzheimer's disease. J Alzheimers Dis. 2017;56(2):441\u20136.","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"4397_CR6","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jalz.2015.05.018","volume":"11","author":"DR Thal","year":"2015","unstructured":"Thal DR, et al. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-beta pathology. Alzheimers Dement. 2015;11(8):975\u201385.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"4397_CR7","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41582-018-0021-z","volume":"14","author":"VL Villemagne","year":"2018","unstructured":"Villemagne VL, et al. Author correction: imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018;14(7):446.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"4397_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrneurol.2018.9","volume":"14","author":"VL Villemagne","year":"2018","unstructured":"Villemagne VL, et al. Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018;14(4):225\u201336.","journal-title":"Nat Rev Neurol"},{"issue":"13","key":"4397_CR9","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286\u201394.","journal-title":"JAMA"},{"issue":"2","key":"4397_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3233\/JAD-122059","volume":"34","author":"DT Chien","year":"2013","unstructured":"Chien DT, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34(2):457\u201368.","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"4397_CR11","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2967\/jnumed.116.185199","volume":"58","author":"L Declercq","year":"2017","unstructured":"Declercq L, et al. Preclinical evaluation of (18)F-JNJ64349311, a novel PET tracer for tau imaging. J Nucl Med. 2017;58(6):975\u201381.","journal-title":"J Nucl Med"},{"issue":"17","key":"4397_CR12","doi-asserted-by":"publisher","first-page":"7350","DOI":"10.1021\/acs.jmedchem.7b00632","volume":"60","author":"LC Gobbi","year":"2017","unstructured":"Gobbi LC, et al. Identification of three novel radiotracers for imaging aggregated tau in Alzheimer's disease with positron emission tomography. J Med Chem. 2017;60(17):7350\u201370.","journal-title":"J Med Chem"},{"key":"4397_CR13","doi-asserted-by":"crossref","unstructured":"Honer M, et al. Preclinical evaluation of (18)F-RO6958948, (11)C-RO6931643 and (11)C-RO6924963 as novel radiotracers for imaging aggregated tau in AD with positron emission tomography. J Nucl Med. 2017.","DOI":"10.2967\/jnumed.117.196741"},{"issue":"10","key":"4397_CR14","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2967\/jnumed.115.171678","volume":"57","author":"ED Hostetler","year":"2016","unstructured":"Hostetler ED, et al. Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med. 2016;57(10):1599\u2013606.","journal-title":"J Nucl Med"},{"issue":"6","key":"4397_CR15","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1021\/acs.jmedchem.8b01759","volume":"62","author":"FJR Rombouts","year":"2019","unstructured":"Rombouts FJR, et al. Discovery of N-(4-[(18)F]Fluoro-5-methylpyridin-2-yl)isoquinolin-6-amine (JNJ-64326067), a new promising tau positron emission tomography imaging tracer. J Med Chem. 2019;62(6):2974\u201387.","journal-title":"J Med Chem"},{"issue":"1","key":"4397_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13024-017-0162-3","volume":"12","author":"L Saint-Aubert","year":"2017","unstructured":"Saint-Aubert L, et al. Tau PET imaging: present and future directions. Mol Neurodegener. 2017;12(1):19.","journal-title":"Mol Neurodegener"},{"issue":"10","key":"4397_CR17","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1021\/acs.jmedchem.6b00166","volume":"59","author":"AM Walji","year":"2016","unstructured":"Walji AM, et al. Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): a positron emission tomography (PET) imaging agent for quantification of neurofibrillary tangles (NFTs). J Med Chem. 2016;59(10):4778\u201389.","journal-title":"J Med Chem"},{"key":"4397_CR18","doi-asserted-by":"crossref","unstructured":"Leuzy A, et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019.","DOI":"10.1038\/s41380-018-0342-8"},{"key":"4397_CR19","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.neuroimage.2017.05.058","volume":"157","author":"A Maass","year":"2017","unstructured":"Maass A, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. Neuroimage. 2017;157:448\u201363.","journal-title":"Neuroimage"},{"key":"4397_CR20","unstructured":"Scholl M, et al. Biomarkers for tau pathology. Mol Cell Neurosci. 2018."},{"issue":"11","key":"4397_CR21","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1002\/j.1460-2075.1985.tb04000.x","volume":"4","author":"CL Masters","year":"1985","unstructured":"Masters CL, et al. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 1985;4(11):2757\u201363.","journal-title":"EMBO J"},{"issue":"1","key":"4397_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0165-0173(00)00019-9","volume":"33","author":"L Buee","year":"2000","unstructured":"Buee L, et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000;33(1):95\u2013130.","journal-title":"Brain Res Brain Res Rev"},{"issue":"7662","key":"4397_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature23002","volume":"547","author":"AWP Fitzpatrick","year":"2017","unstructured":"Fitzpatrick AWP, et al. Cryo-EM structures of tau filaments from Alzheimer's disease. Nature. 2017;547(7662):185\u201390.","journal-title":"Nature"},{"issue":"4","key":"4397_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0896-6273(89)90210-9","volume":"3","author":"M Goedert","year":"1989","unstructured":"Goedert M, et al. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron. 1989;3(4):519\u201326.","journal-title":"Neuron"},{"issue":"1","key":"4397_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrneurol.2015.225","volume":"12","author":"K Iqbal","year":"2016","unstructured":"Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: the story so far. Nat Rev Neurol. 2016;12(1):15\u201327.","journal-title":"Nat Rev Neurol"},{"key":"4397_CR26","doi-asserted-by":"crossref","unstructured":"Falcon B, et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature. 2019.","DOI":"10.1038\/s41586-019-1026-5"},{"issue":"2","key":"4397_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s004010000283","volume":"101","author":"T Arai","year":"2001","unstructured":"Arai T, et al. Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick's disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol. 2001;101(2):167\u201373.","journal-title":"Acta Neuropathol"},{"issue":"7721","key":"4397_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41586-018-0454-y","volume":"561","author":"B Falcon","year":"2018","unstructured":"Falcon B, et al. Structures of filaments from Pick's disease reveal a novel tau protein fold. Nature. 2018;561(7721):137\u201340.","journal-title":"Nature"},{"issue":"1","key":"4397_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40478-019-0682-x","volume":"7","author":"Y Fichou","year":"2019","unstructured":"Fichou Y, et al. The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention? Acta Neuropathol Commun. 2019;7(1):31.","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"4397_CR30","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s12031-011-9589-0","volume":"45","author":"DW Dickson","year":"2011","unstructured":"Dickson DW, et al. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci. 2011;45(3):384\u20139.","journal-title":"J Mol Neurosci"},{"issue":"5","key":"4397_CR31","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/jnen\/64.5.420","volume":"64","author":"RT Mott","year":"2005","unstructured":"Mott RT, et al. Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias. J Neuropathol Exp Neurol. 2005;64(5):420\u20138.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"15","key":"4397_CR32","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1016\/j.bmcl.2015.05.035","volume":"25","author":"M Gao","year":"2015","unstructured":"Gao M, Wang M, Zheng QH. Fully automated synthesis of [(18)F]T807, a PET tau tracer for Alzheimer's disease. Bioorg Med Chem Lett. 2015;25(15):2953\u20137.","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"4397_CR33","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.bmc.2014.11.040","volume":"23","author":"H Schieferstein","year":"2015","unstructured":"Schieferstein H, et al. Selective binding to monoamine oxidase a: in vitro and in vivo evaluation of (18)F-labeled beta-carboline derivatives. Bioorg Med Chem. 2015;23(3):612\u201323.","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"4397_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/bc500475e","volume":"26","author":"O Jacobson","year":"2015","unstructured":"Jacobson O, Kiesewetter DO, Chen X. Fluorine-18 radiochemistry, labeling strategies and synthetic routes. Bioconjug Chem. 2015;26(1):1\u201318.","journal-title":"Bioconjug Chem"},{"issue":"2","key":"4397_CR35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/mds.27271","volume":"33","author":"C Vermeiren","year":"2018","unstructured":"Vermeiren C, et al. The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. Mov Disord. 2018;33(2):273\u201381.","journal-title":"Mov Disord"},{"issue":"1","key":"4397_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13195-017-0253-y","volume":"9","author":"KP Ng","year":"2017","unstructured":"Ng KP, et al. Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain. Alzheimers Res Ther. 2017;9(1):25.","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"4397_CR37","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/ana.24517","volume":"78","author":"M Marquie","year":"2015","unstructured":"Marquie M, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787\u2013800.","journal-title":"Ann Neurol"},{"issue":"1","key":"4397_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40478-019-0686-6","volume":"7","author":"C Aguero","year":"2019","unstructured":"Aguero C, et al. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol Commun. 2019;7(1):37.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"4397_CR39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/mds.26834","volume":"32","author":"JL Whitwell","year":"2017","unstructured":"Whitwell JL, et al. [(18) F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Mov Disord. 2017;32(1):124\u201333.","journal-title":"Mov Disord"},{"issue":"4","key":"4397_CR40","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ana.25060","volume":"82","author":"DR Schonhaut","year":"2017","unstructured":"Schonhaut DR, et al. (18) F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: a multicenter study. Ann Neurol. 2017;82(4):622\u201334.","journal-title":"Ann Neurol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04397-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04397-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04397-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T23:06:05Z","timestamp":1593471965000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04397-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["4397"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04397-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,1]]},"assertion":[{"value":"11 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"\u2022 Heiko Kroth is an employee of AC Immune and holds shares of AC Immune.\u2022 Felix Oden is an employee of LMI.\u2022 Jerome Molette is an employee of AC Immune and holds shares of AC Immune.\u2022 Hanno Schieferstein has no conflict of interest.\u2022 Francesca Capotosti is an employee of AC Immune.\u2022 Andre Mueller is an employee of LMI.\u2022 Mathias Berndt is an employee of LMI.\u2022 Heribert Schmitt-Willich is an employee of LMI.\u2022 Vincent Darmency is an employee of AC Immune.\u2022 Emanuele Gabellieri is an employee of AC Immune and holds shares of AC Immune.\u2022 C\u00e9dric Boudou is an employee of AC Immune and holds shares of AC Immune.\u2022 Tanja Juergens is an employee of AC Immune.\u2022 Yvan Varisco is an employee of AC Immune and holds shares of AC Immune.\u2022 Efthymia Vokali is an employee of AC Immune.\u2022 David Tadeusz Hickman is an employee of AC Immune and holds shares of AC Immune.\u2022 Gilles Tamagnan has no conflict of interest.\u2022 Andrea Pfeifer is an employee of AC Immune and holds shares of AC Immune.\u2022 Ludger Dinkelborg is an employee of LMI.\u2022 Andreas Muhs was an employee of AC Immune and holds shares of AC Immune.\u2022 Andrew Wills Stephens is an employee of LMI.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"A female rhesus macaque (<i>Macaca mulatta<\/i>) housed at the Yale University School of Medicine in New Haven, Connecticut, was used as research subject. PET imaging studies were carried out under institutional animal care protocols complying with federal regulations. Animal care approval and oversight for this study were provided by the Yale University IACUC. All mice experiments were done adhering to all applicable international, national, and\/or institutional guidelines for the care and use of animals. This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All human tissues provided by Tissue Solutions have been obtained according to the legal and ethical requirements of the country of collection, with the approval of an ethics committee (or similar) and with anonymous consent from the donor or nearest relative. We work only with sources who comply with the most stringent international ethical guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement of tissue solutions (<!--ExternalRef removed-->\n                    https:\/\/www.tissue-solutions.com<!--Too long, content removed-->"}}]}}